Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| PMV Pharmaceuticals, Inc.PMVP · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $116.6M[1] |
| Warnings | short runway, thin datanot computable: degenerate inputs, fortress balance sheet |
| Inputs computable | 6 of 14 |
| Graded from | filings received through Mar 6, 2026217 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $1.492026-10-08; market equity $79.7M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 6, 2026; the document on sec.gov.
We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 72.7 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (2.7%) | [1,3-5] | (6.6%) | 72.7 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 48.2 | |||||||
| Twelve-month failure probability | 0.44% | 0.07% | 81.8 | 248 | 2026-06-30 | ||
| Altman Z double-prime | (2.34) | [1,6-11] | (0.31) | 46.5 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| one or more required annual facts are missing | |||||||
| Current ratio | 10.09x | [6-7] | 2.96x | 16.2 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 62.1 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 0 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | (24.5%) | [1,5,12-13] | 2.1% | 88.2 | 704 | 2025-12-31 | |
| Net share issuance, one year | 2.7% | [14-15] | 2.5% | 36.0 | 634 | 2026-03-03 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (13.6%) | 8.0% | 36 | hotter than 36 of 100 peers |
| Distance from 52-week high | (17.2%) | (31.4%) | 69 | closer to its high than 69 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (92.4%) | (1.0%) | 6 | pricier than 94 of 100 peers |
| Book value to price | 0.90 | 0.28 | 84 | pricier than 16 of 100 peers |
| Sales to price | not computable | 0.31 | required accounting or market input is missing | |
| Composite equity issuance, five years | 17.7% | 20.3% | 48 | more equity-funded than 48 of 100 peers |
| Relative strength against the sector, log excess return | (0.36) | (0.14) | 36 | ahead of 36 of 100 peers |
Inputs: market equity $79.7M; EBIT -$86.2M; free cash flow -$73.6M; book equity $71.5M; cash $12.5M[16].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (40.6%) | ✗ fail[3,5] |
| Operating cash flow above zero | -$73.6M | ✗ fail[4] |
| Return on assets improved | (17.4 pts) | ✗ fail[3,5,12,17] |
| Operating cash flow exceeds net income | $4.2M | ✓ pass[3-4] |
| Long-term leverage fell | n/a[1,5,12] | |
| Current ratio improved | (213.0 pts) | ✗ fail[6-7,18-19] |
| No new shares issued | 2.7% | ✗ fail[14-15] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[5,12] | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $12.5M[2] |
| Operating cash flow, four quarters | -$71.3M[2,4,20-23] |
| Months of runway | 2.1 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 56 |
| 10-Q received Aug 14, 2026 | |
| Median daily dollar volume | $479,351 |
| 63 sessions | |
| Days since newest grade input | 217 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $116.6M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 2 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $12.5M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 3 | net income | us-gaap:NetIncomeLoss | -$77.7M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$73.6M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 5 | assets | us-gaap:Assets | $191.3M | 2024-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 6 | current assets | us-gaap:AssetsCurrent | $115.2M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 7 | current liabilities | us-gaap:LiabilitiesCurrent | $11.4M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 8 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$446.5M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 9 | operating income | us-gaap:OperatingIncomeLoss | -$86.2M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 10 | book equity | us-gaap:StockholdersEquity | $104.7M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 11 | liabilities | us-gaap:Liabilities | $11.8M | 2025-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 12 | assets | us-gaap:Assets | $252.2M | 2023-12-31 | 2025-03-03 | 10-K | filing · viewer · series |
| 13 | assets | us-gaap:Assets | $270.3M | 2022-12-31 | 2024-02-29 | 10-K | filing · viewer · series |
| 14 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 53,329,392 | 2026-03-03 | 2026-03-06 | 10-K | filing · viewer · series |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 51,933,604 | 2025-03-03 | 2025-03-03 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 53,458,058 | 2026-08-14 | 2026-08-14 | 10-Q | filing · viewer · series |
| 17 | net income | us-gaap:NetIncomeLoss | -$58.7M | 2024-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 18 | current assets | us-gaap:AssetsCurrent | $175.7M | 2024-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 19 | current liabilities | us-gaap:LiabilitiesCurrent | $14.4M | 2024-12-31 | 2026-03-06 | 10-K | filing · viewer · series |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$34.3M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$19.7M | 2026-03-31 | 2026-05-12 | 10-Q | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$56.4M | 2025-09-30 | 2025-11-12 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$36.6M | 2025-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.